Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Ma

Showing results (111-120 of 357) with videos related to

Pageof 36
Sort By:
Drugs|June 2, 2023
Targeting IL-23 for IBD: Rationale and Progress to DateSudheer K Vuyyuru, Lisa M Shackelton, Jurij Hanzel, et al.
Best Practice & Research. Clinical Gastroenterology|July 23, 2019
Targeting anti-fibrotic pathways in Crohn's disease - The final frontier?Christopher Ma, Vipul Jairath, Benjamin Click, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 26, 2020
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel DiseaseAhmed Almradi, Jurij Hanzel, Rocio Sedano, et al.
The American Journal of Gastroenterology|October 25, 2018
Strategies for Detecting Colorectal Cancer in Patients with Inflammatory Bowel Disease: A Cochrane Systematic Review and Meta-AnalysisWilliam A Bye, Christopher Ma, Tran M Nguyen, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 16, 2023
Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn's disease: A Canadian multi-center studyTalat Bessissow, Neeraj Narula, Christopher Ma, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 31, 2024
Healthcare resource utilization following ustekinumab initiation among bio-naïve Canadian patients with moderately-to-severely active Crohn's diseaseTalat Bessissow, Neeraj Narula, Christopher Ma, et al.
Journal of Crohn'S & Colitis|October 11, 2022
Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction StudiesPaul Bahnam, Jurij Hanzel, Christopher Ma, et al.
Shoulder & Elbow|November 17, 2023
Outcomes of reverse shoulder arthroplasty in patients under 55 years old: Results from the New Zealand joint registryRyan Gao, Michael van der Merwe, Brendan Coleman, et al.
Journal of the Canadian Association of Gastroenterology|February 14, 2023
The Impact of the COVID-19 Pandemic on IBD Care in Alberta: Patient and Provider PerspectivesMonica Dahiya, Lily Olayinka, Gilaad G Kaplan, et al.
Journal of Crohn'S & Colitis|August 12, 2025
Impact of Concomitant Corticosteroid Use on Adverse Events in Ulcerative Colitis Clinical TrialsHasan Hamam, Parambir S Dulai, John K Marshall, et al.
Pageof 36

Showing results (111-120 of 357) with videos related to

Sort By:
Pageof 36
Drugs|June 2, 2023
Targeting IL-23 for IBD: Rationale and Progress to DateSudheer K Vuyyuru, Lisa M Shackelton, Jurij Hanzel, et al.
Best Practice & Research. Clinical Gastroenterology|July 23, 2019
Targeting anti-fibrotic pathways in Crohn's disease - The final frontier?Christopher Ma, Vipul Jairath, Benjamin Click, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 26, 2020
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel DiseaseAhmed Almradi, Jurij Hanzel, Rocio Sedano, et al.
The American Journal of Gastroenterology|October 25, 2018
Strategies for Detecting Colorectal Cancer in Patients with Inflammatory Bowel Disease: A Cochrane Systematic Review and Meta-AnalysisWilliam A Bye, Christopher Ma, Tran M Nguyen, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 16, 2023
Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn's disease: A Canadian multi-center studyTalat Bessissow, Neeraj Narula, Christopher Ma, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 31, 2024
Healthcare resource utilization following ustekinumab initiation among bio-naïve Canadian patients with moderately-to-severely active Crohn's diseaseTalat Bessissow, Neeraj Narula, Christopher Ma, et al.
Journal of Crohn'S & Colitis|October 11, 2022
Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction StudiesPaul Bahnam, Jurij Hanzel, Christopher Ma, et al.
Shoulder & Elbow|November 17, 2023
Outcomes of reverse shoulder arthroplasty in patients under 55 years old: Results from the New Zealand joint registryRyan Gao, Michael van der Merwe, Brendan Coleman, et al.
Journal of the Canadian Association of Gastroenterology|February 14, 2023
The Impact of the COVID-19 Pandemic on IBD Care in Alberta: Patient and Provider PerspectivesMonica Dahiya, Lily Olayinka, Gilaad G Kaplan, et al.
Journal of Crohn'S & Colitis|August 12, 2025
Impact of Concomitant Corticosteroid Use on Adverse Events in Ulcerative Colitis Clinical TrialsHasan Hamam, Parambir S Dulai, John K Marshall, et al.
Pageof 36